334 



- 91 - 



cigarettt Industry ultimately may b« In greater trouble In this area 

 than In the lung cancer field.": and (c), that "The Cardiovascular 

 Effects in smoke are believed to be mainly due to nicotine and have 

 been thoroughly explored in literature and conference." (Press 

 Release - Tobacco Products Liability Project . March 26, 1988, p. 3) 



2. iM Tar and Low nicotine Cigarette Labeling. Advertising and ProBotlon 

 Falls te disclose contraindlcatlotis. effectiveness, side effects, etc . 



As noted earlier, section 502(n) of the FDCA specifically requires that 

 drug manufacturers disclose contraindications, side effects and the 

 effectiveness of their product. Although a federally mandated warning 

 label appears on the package and advertisements of cigarette products, the 

 message contained is far from complete. If low tar/low nicotine 

 cigarettes were treated as drugs It would be Incumbent upon the FOA to 

 require that proper labeling and disclosure be provided on all low tar and 

 nicotine cigarettes to ensure that consumers are not mislead about the 

 effects and or benefits of these products. 



ConsuMrs h«vt « right to know the pharmacological effects of these 

 products Just as they do with respect to other drug products. The 

 labeling for "Nicorette* gum for example, a prescription drug used as a 

 tobacco substitute, contains a lengthy description of the product. Its 

 direction for use, contraindications, and side effects. The labeling 

 requirements for oral contraceptives warns the consumer that use of 



